AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
As disclosed previously, on August 11, 2017, Aytu BioScience, Inc. (the Company) entered into a Securities Purchase Agreement (SPA) with certain purchasers (the Purchasers) of the Companys securities. Among other terms, the SPA granted the Purchasers the right to participate in future financing transactions by the Company and also prohibited the Company from entering into certain variable rate transactions, until August 11, 2022. On April 24, 2019, the Company entered into an amendment to the SPA (the Amendment) in accordance with the terms of the SPA. Under the Amendment, the Purchasers continue to have a right to participate in future financing transactions by the Company until August 11, 2019, but the Amendment reduces and simplifies some of the notice requirements of the Company in connection with this right. In addition, the Amendment removes the prohibition against the Company engaging in certain other transactions. No consideration was given by the Company in exchange for Purchasers\’ agreement to this Amendment.
The foregoing summary of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amendment, the form of which is filed as Exhibit 10.1 to this report and is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
On April 26, 2019, the Company issued a press release announcing the submission of ZolpiMistTM for approval by the Australian Therapeutic Goods Administration. A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) The following exhibit is being filed herewith:
AYTU BIOSCIENCE, INC Exhibit
EX-10.1 2 aytu_ex101.htm MATERIAL CONTRACTS Blueprint Exhibit 10.1 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT This AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT (this “Amendment”) is made effective as of April 24,…
To view the full exhibit click
About AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU)
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company also markets Primsol (trimethoprim hydrochloride), a trimethoprim-only oral solution for urinary tract infections. The Company’s pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men.
An ad to help with our costs